Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Part A: Phase 1, Single- Ascending Dose Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of Agomelatine in Healthy Participants. Part B & Part D: Phase 1, Double-Blind, Placebo-Controlled, 4-Part, Single- and Multiple-Ascending Dose Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of SPT-320 in Healthy Participants

Next Previous
Trial Profile

Part A: Phase 1, Single- Ascending Dose Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of Agomelatine in Healthy Participants. Part B & Part D: Phase 1, Double-Blind, Placebo-Controlled, 4-Part, Single- and Multiple-Ascending Dose Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of SPT-320 in Healthy Participants

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Agomelatine prodrug (Primary)
  • Indications Anxiety disorders; Mood disorders
  • Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept
  • Sponsors Seaport Therapeutics

Most Recent Events

  • 10 Nov 2025 New trial record
  • 13 Sep 2025 Status changed to recruiting.
  • 13 Sep 2025 According to PureTech media release, today announced that the first participant has been dosed in the phase 1 study of GlyphAgo.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top